223 related articles for article (PubMed ID: 11591795)
1. Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats.
Abe M; Shibata K; Akatsu H; Shimizu N; Sakata N; Katsuragi T; Okada H
J Immunol; 2001 Oct; 167(8):4651-60. PubMed ID: 11591795
[TBL] [Abstract][Full Text] [Related]
2. Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes.
Kodani M; Sakata N; Takano Y; Kamiya H; Katsuragi T; Hugli TE; Abe M
Immunopharmacology; 2000 Sep; 49(3):263-74. PubMed ID: 10996024
[TBL] [Abstract][Full Text] [Related]
3. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma.
Drouin SM; Kildsgaard J; Haviland J; Zabner J; Jia HP; McCray PB; Tack BF; Wetsel RA
J Immunol; 2001 Feb; 166(3):2025-32. PubMed ID: 11160252
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation.
Baelder R; Fuchs B; Bautsch W; Zwirner J; Köhl J; Hoymann HG; Glaab T; Erpenbeck V; Krug N; Braun A
J Immunol; 2005 Jan; 174(2):783-9. PubMed ID: 15634899
[TBL] [Abstract][Full Text] [Related]
5. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils.
de Vries B; Köhl J; Leclercq WK; Wolfs TG; van Bijnen AA; Heeringa P; Buurman WA
J Immunol; 2003 Apr; 170(7):3883-9. PubMed ID: 12646657
[TBL] [Abstract][Full Text] [Related]
6. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells.
Monsinjon T; Gasque P; Chan P; Ischenko A; Brady JJ; Fontaine MC
FASEB J; 2003 Jun; 17(9):1003-14. PubMed ID: 12773483
[TBL] [Abstract][Full Text] [Related]
7. Expression and function of the C5a receptor in rat alveolar epithelial cells.
Riedemann NC; Guo RF; Sarma VJ; Laudes IJ; Huber-Lang M; Warner RL; Albrecht EA; Speyer CL; Ward PA
J Immunol; 2002 Feb; 168(4):1919-25. PubMed ID: 11823527
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.
Staab EB; Sanderson SD; Wells SM; Poole JA
Int Immunopharmacol; 2014 Aug; 21(2):293-300. PubMed ID: 24859057
[TBL] [Abstract][Full Text] [Related]
9. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression.
Sayah S; Ischenko AM; Zhakhov A; Bonnard AS; Fontaine M
J Neurochem; 1999 Jun; 72(6):2426-36. PubMed ID: 10349852
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha.
Czermak BJ; Sarma V; Bless NM; Schmal H; Friedl HP; Ward PA
J Immunol; 1999 Feb; 162(4):2321-5. PubMed ID: 9973510
[TBL] [Abstract][Full Text] [Related]
11. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy.
Drouin SM; Corry DB; Hollman TJ; Kildsgaard J; Wetsel RA
J Immunol; 2002 Nov; 169(10):5926-33. PubMed ID: 12421977
[TBL] [Abstract][Full Text] [Related]
12. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma.
Engelke C; Wiese AV; Schmudde I; Ender F; Ströver HA; Vollbrandt T; König P; Laumonnier Y; Köhl J
J Immunol; 2014 Dec; 193(11):5387-401. PubMed ID: 25355927
[TBL] [Abstract][Full Text] [Related]
13. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone.
Murai A; Abe M; Hayashi Y; Sakata N; Katsuragi T; Tanaka K
J Pharmacol Exp Ther; 2005 Feb; 312(2):432-40. PubMed ID: 15470084
[TBL] [Abstract][Full Text] [Related]
14. Respiratory Syncytial Virus Exacerbates OVA-mediated asthma in mice through C5a-C5aR regulating CD4
Hu X; Li X; Hu C; Qin L; He R; Luo L; Tang W; Feng J
Sci Rep; 2017 Nov; 7(1):15207. PubMed ID: 29123203
[TBL] [Abstract][Full Text] [Related]
15. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
Gu H; Fisher AJ; Mickler EA; Duerson F; Cummings OW; Peters-Golden M; Twigg HL; Woodruff TM; Wilkes DS; Vittal R
FASEB J; 2016 Jun; 30(6):2336-50. PubMed ID: 26956419
[TBL] [Abstract][Full Text] [Related]
16. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.
Li L; Chen L; Zang J; Tang X; Liu Y; Zhang J; Bai L; Yin Q; Lu Y; Cheng J; Fu P; Liu F
Metabolism; 2015 May; 64(5):597-610. PubMed ID: 25682062
[TBL] [Abstract][Full Text] [Related]
17. The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to C5a(desArg).
Werfel T; Oppermann M; Butterfield JH; Begemann G; Elsner J; Götze O; Zwirner J
Scand J Immunol; 1996 Jul; 44(1):30-6. PubMed ID: 8693289
[TBL] [Abstract][Full Text] [Related]
18. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease.
Shushakova N; Skokowa J; Schulman J; Baumann U; Zwirner J; Schmidt RE; Gessner JE
J Clin Invest; 2002 Dec; 110(12):1823-30. PubMed ID: 12488432
[TBL] [Abstract][Full Text] [Related]
19. Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a.
Gutzmer R; Köther B; Zwirner J; Dijkstra D; Purwar R; Wittmann M; Werfel T
J Invest Dermatol; 2006 Nov; 126(11):2422-9. PubMed ID: 16778800
[TBL] [Abstract][Full Text] [Related]
20. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse.
Van Beek J; Bernaudin M; Petit E; Gasque P; Nouvelot A; MacKenzie ET; Fontaine M
Exp Neurol; 2000 Jan; 161(1):373-82. PubMed ID: 10683302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
